Original
statement: “When prospective-cohort findings converge with biological mechanism, biomarker studies, and randomized trials of intermediate endpoints (satisfying Bradford-Hill criteria), they jointly support causal inference sufficient for policy — and because hard-endpoint dietary RCTs are frequently infeasible, unblindable, and undermined by poor compliance and dropout, withholding inference until such trials exist is not a viable alternative.”
Validity verdict (step 6)
corrected, checked. Reconstruction: premises are (a) cohort + mechanism + biomarker + intermediate-endpoint-RCT evidence converge, and (b) hard-endpoint dietary RCTs are usually infeasible; conclusion is that the triangulated package is a causal basis “sufficient for policy.” Two load-bearing steps, traced separately:
- Convergence step. Conditional on the premises, convergence of evidence types with different failure modes does make a purely non-causal explanation of all of them jointly less likely — this part goes through as an evidential-strengthening claim. But “sufficient for policy” faces a surviving undercutting defeater that does not deny the premises: the corroborating trials are of intermediate endpoints (lipids, BP), and surrogate-endpoint agreement is a historically fallible predictor of hard clinical outcomes (canonical counterexamples: torcetrapib and CETP inhibitors, niacin, and other agents that moved surrogates the “right” way yet failed or harmed on events). So full convergence on surrogates + mechanism + cohort can co-occur with no (or opposite) hard-endpoint effect. That breaks reason→“sufficient” while leaving “strengthens / supports” intact.
- RCT-infeasibility step. This limb establishes only that triangulation is the best available basis, not that it is adequate: the unavailability of a better tool is a non-sequitur for the reliability of the tool in hand. Concluding “adequate/sufficient” partly on the ground that nothing better exists is the specific gap.
Both faults are cured by the weaker conclusion — “jointly strengthen causal inference and are the best available policy basis, adequate only when the corroborating evidence is itself strong and concordant” — which is immune to the surrogate-fallibility defeater. Hence
correctedto that form. The body’s own noted weak point (triangulation licenses confidence only when corroborating evidence is strong) is folded into the corrected statement.
Reasoning
Two linked steps. (1) Triangulation upgrades association to causation: a prospective cohort alone yields a statistical association, not causation, but when the cohort association is corroborated by a biological mechanism, by biomarker studies, and by randomized trials of intermediate outcomes (e.g. lipids, blood pressure), the Bradford-Hill criteria — strength, consistency, temporality, dose-response (biological gradient), plausibility, coherence, experimental evidence — are collectively met, and convergence across independent evidence types with different failure modes makes a non-causal explanation for all of them jointly implausible (Satija’s Mediterranean-diet example: concordant observational, RCT, single-nutrient, and biomarker evidence). (2) The RCT alternative is often unavailable: hard-endpoint dietary trials cannot be blinded, suffer 30–40% one-year dropout and poor adherence (the WHI low-fat arm never reached its 20%-fat target, yielding an uninformative null), take decades, and are frequently unethical — so demanding a hard-endpoint RCT before acting would leave most dietary questions permanently unanswerable. Therefore, for policy, well-triangulated cohort evidence is both the best available and adequate basis. The inference is valid as a claim about evidential convergence; its weak point is that triangulation only licenses causal confidence when the corroborating trial/mechanistic evidence is itself strong and concordant — where intermediate-outcome trials are small or selectively reported (as the critics allege), the convergence is weaker than claimed.